11月19日，汇宇制药跌5.2%，截至发稿，报20.61元/股，成交5827.48万元，换手率0.80%，总市值87.30 亿元。 资料显示，四川汇宇制药股份有限公司位于四川省内江市市中区汉阳路333号3幢，成立日期2010年10月 12日，上市日期2021年10月26日，公司主营业务涉及肿瘤领域药物和复杂注射剂药物的研发、生产和国 内外销售。主营业务收入构成为：药品销售97.27%，技术服务1.66%，其他1.07%。 从汇宇制药十大流通股东角度 数据显示，平安基金旗下1只基金位居汇宇制药十大流通股东。平安医疗健康混合A（003032）三季度 新进十大流通股东，持有股数683.78万股，占流通股的比例为1.99%。根据测算，今日浮亏损失约 772.68万元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 平安医疗健康混合A（003032）成立日期2017年11月24日，最新规模20.28亿。今年以来收益63.9%，同 类排名315/8138；近一年 ...

Core Viewpoint - Huayu Pharmaceutical's stock increased by 5.03% on October 31, reaching 21.30 CNY per share, with a total market capitalization of 9.023 billion CNY [1] Company Overview - Sichuan Huayu Pharmaceutical Co., Ltd. was established on October 12, 2010, and listed on October 26, 2021. The company focuses on the research, production, and sales of drugs in the oncology field and complex injectable drugs [1] - The main revenue composition includes 97.27% from drug sales, 1.66% from technical services, and 1.07% from other sources [1] Shareholder Information - Ping An Fund's Ping An Medical Health Mixed A (003032) entered the top ten circulating shareholders of Huayu Pharmaceutical in the third quarter, holding 6.8378 million shares, which is 1.99% of the circulating shares [2] - The estimated floating profit from this investment is approximately 6.9746 million CNY [2] Fund Performance - Ping An Medical Health Mixed A (003032) was established on November 24, 2017, with a current size of 2.028 billion CNY. The fund has achieved a year-to-date return of 56.7%, ranking 794 out of 8154 in its category [2] - Over the past year, the fund's return is 47.82%, ranking 1222 out of 8046, and since inception, it has returned 143.53% [2]

Core Insights - The AI Fund Ping An Medical Health Mixed A (003032) reported a profit of 352 million yuan for the first half of 2025, with a weighted average profit per fund share of 1.0034 yuan [2] - The fund's net value growth rate was 57.41% during the reporting period, with a total fund size of 966 million yuan as of the end of June [2] - The fund focuses on long-term investments in pharmaceutical and medical stocks, with a current unit net value of 3.103 yuan as of September 3 [2] Performance Metrics - As of September 3, the fund's one-year cumulative net value growth rate was 111.92%, ranking 5th out of 136 comparable funds [5] - The fund's three-month net value growth rate was 32.83%, ranking 29th out of 138 comparable funds [5] - The fund's three-year Sharpe ratio was 0.4698, ranking 15th out of 105 comparable funds [25] Investment Strategy - The fund manager emphasized the importance of sub-industry prosperity in investment strategy, focusing on companies with valuation advantages in the innovative drug sector [2] - The fund's top ten holdings include companies such as CloudTop New Medicine, Innovent Biologics, and BeiGene, indicating a concentrated investment approach [40] Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately -202.85, compared to the industry average of 120.96 [9] - The weighted average price-to-book (P/B) ratio was about 7.89, while the industry average was 4.07 [9] - The weighted average price-to-sales (P/S) ratio was approximately 14.98, compared to the industry average of 6.52 [9] Growth Metrics - For the first half of 2025, the fund's weighted average revenue growth rate was 0.17%, while the weighted average net profit growth rate was -0.21% [16] - The fund's weighted annualized return on equity was -0.04% [16] Fund Composition - As of June 30, 2025, the fund had 24,900 holders, with a total of 395 million shares held [34] - Institutional investors held 64.36% of the fund's shares, while individual investors accounted for 35.64% [34] - The fund's turnover rate for the last six months was approximately 143.02%, consistently below the industry average [37]

Group 1 - The core point of the article highlights the performance of Ping An Medical Health Mixed A fund, which has shown significant returns over various time frames, including a year-to-date return of 90.28% [1] - As of June 30, 2025, the fund's total assets amounted to 966 million yuan [1] - The fund's top ten stock holdings account for a combined 75.91% of its portfolio, indicating a concentrated investment strategy [1] Group 2 - The fund was established on November 24, 2017, and is managed by Zhou Sicong [1] - Recent performance metrics include a weekly return of 5.57% and a three-month return of 49.52% [1] - The top ten holdings include companies such as CloudTop New Medicine, Innovent Biologics, and BeiGene, showcasing a focus on the healthcare sector [1]

Group 1 - The majority of stock and mixed funds achieved positive returns, with 89.57% reporting gains, and 52 funds exceeding a 5% return [1][2] - The Shanghai Composite Index rose by 0.43% to close at 3399.77 points, while the Shenzhen Component Index increased by 0.65%, and the ChiNext Index rose by 1.07% [1] - The top-performing sectors included pharmaceuticals, agriculture, and textiles, with respective increases of 2.30%, 1.72%, and 1.61% [1] Group 2 - The average net value growth rate for stock and mixed funds on June 9 was 0.68%, with 52 funds achieving over 5% growth [1][2] - The leading fund in terms of net value growth was Red Soil Innovation Healthcare Stock, with a growth rate of 7.36% [2] - Among the funds with over 5% growth, 9 belonged to Ping An Fund, while Great Wall Fund and Penghua Fund had 8 and 6 funds respectively [1][2] Group 3 - The funds with the highest net value declines included Gold Stock ETF, which fell by 1.11%, followed by Ping An and Guotai ETFs with declines of 1.10% and 1.09% respectively [2][3] - The data indicates a significant focus on healthcare-related funds, with multiple funds from Ping An Fund showing strong performance [1][2] - The report highlights the volatility in the gold sector, as evidenced by the performance of various gold-related ETFs [2][3]